Ana Beatriz Teixeira Frederico

Ms. Ana Beatriz Teixeira Frederico

Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DCDanielle Cunha
Danielle Cunha
Ana Beatriz Teixeira FredericoAna Beatriz Teixeira Frederico
Ana Beatriz Teixeira Frederico
TATamiris Azamor
Tamiris Azamor
JMJuliana Melgaço
Juliana Melgaço
PNPatrícia Neves
Patrícia Neves
SMSotiris Missailidis
Sotiris Missailidis
The depth and versatility of siRNA technologies enable their use in disease targets that are undruggable by small molecules or that seek to achieve a refined turn-off of the genes for any therapeutic area. Major extracellular barriers are enzymatic degradation of siRNAs by serum endonucleases and RNAases, renal clearance of the siRNA delivery system, the impermeability of biological membranes for siRNA, activation of the immune system, plasma protein sequestration, and capillary endothelium crossing. To overcome the intrinsic difficulties of the use of siRNA molecules, therapeutic applications require nanometric delivery carriers aiming to protect double-strands and deliver molecules to target cells. This review discusses the history of siRNAs, siRNA design, and delivery strategies, with a focus on progress made regarding siRNA molecules in clinical trials and how siRNA has become a valuable asset for biopharmaceutical companies.

30 August 2022 in Viruses
Verified
Journal Article
Open access
PDF file
TATamiris Azamor
Tamiris Azamor
IHIngrid Siciliano Horbach
Ingrid Siciliano Horbach
DCDanielle Cunha
Danielle Cunha
JMJuliana Melgaço
Juliana Melgaço
ASAndréa Marques Vieira da Silva
Andréa Marques Vieira da Silva
SMSotiris Missailidis
Sotiris Missailidis
Infections caused by SARS-CoV-2 induce a severe acute respiratory syndrome called COVID-19 and have led to more than six million deaths worldwide. Vaccination is the most effective preventative measure, and cellular and humoral immunity is crucial to developing individual protection. Here, we aim to investigate hybrid immunity against SARS-CoV-2 triggered by the ChAadOx1 nCoV-19 vaccine in a Brazilian cohort. We investigated the immune response from ChAadOx1 nCoV-19 vaccination in naïve (noCOVID-19) and previously infected individuals (COVID-19) by analyzing levels of D-dimers, total IgG, neutralizing antibodies (Nabs), IFN-γ (interferon-γ) secretion, and immunophenotyping of memory lymphocytes. No significant differences in D-dimer levels were observed 7 or 15 days after vaccination (DAV). All vaccinated individuals presented higher levels of total IgG or Nabs with a positive correlation (R = 0.88). Individuals in the COVID-19 group showed higher levels of antibody and memory B cells, with a faster antibody response starting at 7 DAV compared to noCOVID-19 at 15 DAV. Further, ChAadOx1 nCoV-19 vaccination led to enhanced IFN-γ production (15 DAV) and an increase in activated T CD4+ naïve cells in noCOVID-19 individuals in contrast with COVID-19 individuals. Hence, our data support that hybrid immunity triggered by ChAadOx1 nCoV-19 vaccination is associated with enhanced humoral response, together with a balanced cellular response.

20 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
MRMomtchilo Russo
Momtchilo Russo
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
BLBruna B. Lins
Bruna B. Lins
VKVictor Kersten
Victor Kersten
PFPaulo C. A. Pernambuco Filho
Paulo C. A. Pernambuco Filho
LMLuciana Mirotti
Luciana Mirotti
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.

9 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MRMomtchilo Russo
Momtchilo Russo
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
BLBruna Bezerra Lins
Bruna Bezerra Lins
VKVictor Kersten
Victor Kersten
PFPaulo C. A. Pernambuco Filho
Paulo C. A. Pernambuco Filho
LMLuciana Mirotti
Luciana Mirotti
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate to COVID-19 constituted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight lost and mortality indicators. However, when compared to the subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine that was more robust than homologous immunity.

1 January 2023
Verified
Conference Paper
Open access
PDF file
GMGabriel Mustafá Misirli
Gabriel Mustafá Misirli
KSKeila Santos
Keila Santos
JFJeanne Dopazo Fernandes
Jeanne Dopazo Fernandes
Maria Helena Melo LimaMaria Helena Melo Lima
Maria Helena Melo Lima
Ana Beatriz Teixeira FredericoAna Beatriz Teixeira Frederico
Ana Beatriz Teixeira Frederico
ESEdimilson Silva
Edimilson Silva
Introduction: Gold nanoparticles (AuNPs) are often used as biosensors in biological markers and also in diagnostic kits. Spherical shaped AuNPs are red. These nanoparticles have high binding affinity with proteins, antibodies and antigens forming stable bioconjugates. Are widely used in lateral flow immunochromatography platform. Therefore, AuNPs are currently one of the main raw materials used to produce various diagnostic kits, including Sars-CoV-2. The assessment of their correct stability directly affects the customized production and quality of the diagnostics kits. Objectives: Evaluate the stability of in-house prepared gold nanoparticle solutions used in the manufacture of diagnostic tests using statistical methods for determining the appropriate shelf life under established storage conditions. Methodology: In-house based on adapted Turkevish method (1951), a gold nanoparticle (AuNP) solution was synthesized and characterized by ultraviolet-visible spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), dynamic scattering (DLS) and laser Doppler electrophoresis (LDE). The solution was analyzed at the time of manufacture (T0) and every 15 days for 90 days, under thermal stress conditions. The evaluation of the stability of the AuNP solution was based on the ISO Guide 35, which statistically evaluates the time that significant change occurs of the evaluation parameters, indicating the end of shelf life at a significance level of 0.05. Results: Statistical analysis shows that at T90 days, one of the evaluated parameters showed a significant change at a significance level of 0.05. |b1| > t95%, n-2 * s(b1) and, therefore, there is statistical evidence that proves that the final solution lost stability in this time. Arrhenius equation was used to determine the shelf life. Where, Storage=25°C, Stress=40°C, Activation Energy (Ea)=3, and then: Thermal Kinetic Ratio (Qt) = 5.2. That is, 2.5 months at 40°C is equivalent to 13 months at 25°C. Conclusion: AuNPs produced in-house have a shelf life of 1 month at room temperature. Based on the analysis of the main control parameters and statistical application, the validity attributable to the AuNP solution under study is 13 months at 25°C, bringing great savings to the production process, without loss of quality. New strategies for evaluating the stability of solutions should be considered in the future.

1 January 2022
Verified
Conference Paper
Open access
PDF file
LMLuciana Mirotti
Luciana Mirotti
MRMomtchilo Russo
Momtchilo Russo
MCMaria Cassia Mendes Correa
Maria Cassia Mendes Correa
MHMario Hirata
Mario Hirata
FSFelipe Silva
Felipe Silva
VKVictor Kersten
Victor Kersten